| 摘要 |
Compositions containing (a) L-carnitine, an acyl L-carnitine, or a pharmacologically acceptable salt therof in combination with (b) an ACE-inhibitor are useful for treating cardiovascular disorders. Orally, parenterally, rectally or transdermally administrable pharmaceutical compositions in unit dosage form contain from about 0.5 to about 2 g of L-carnitine, or an aquimolar amount of an acyl L-carnitine or a pharmacologically acceptable salt thereof, and, e.g., from about 5 to about 20 mg of the ACE-inhibitor lisinopril.
|
